UPPSALA, Sweden, March 29, 2023 (GLOBE NEWSWIRE) — Olink Holding AB (publ) (Nasdaq: OLK) at this time introduced that the regional proteomic facility, D-CYPHR in Cape City, South Africa has adopted Olink expertise and has develop into the primary service supplier utilizing the Olink® Goal and Olink® Flex platforms for focused protein biomarker discovery on the African continent.
D-CYPHR is a brand new facility co-founded by the Centre for Proteomic and Genomic Analysis (CPGR) and the Institute of Infectious Illness and Molecular Drugs (IDM) beneath the DIPLOMICS community programme, an initiative by the South African Division of Science and Innovation (DSI). D-CYPHR permits entry to proteomics and metabolomics platforms and data, supporting advanced scientific and organic analysis not doable elsewhere on this area.
“One of many targets of the DIPLOMICS programme is to allow and enhance entry to cutting-edge ‘omics applied sciences and experience. Via the D-CYPHR laboratory, we’re excited in regards to the introduction of the Olink expertise, which can dramatically enhance the standard and throughput of superior proteomics analysis in South Africa,” mentioned Dr Tim Newman, Program Supervisor for DIPLOMICS.
Among the many first tasks to profit from Olink expertise shall be these directed towards COVID-19 and tuberculosis analysis. The Olink panels for focused protein biomarker discovery allow quicker, better-informed selections in human protein biomarker analysis by offering high-multiplex immunoassays advantages with out compromising information high quality or efficiency.
“The flexibility to quantify giant panels of secreted and cell floor antigens in scientific samples from tuberculosis sufferers utilizing excessive throughput, multiplexed Olink assays will allow new insights into immunopathogenesis on this essential infectious illness,” commented Professor Jonathan Blackburn, Deputy Director of the IDM.
“That is an thrilling alternative to develop significant evaluation of adjustments in proteomic profiles and their related impacts. These analyses will assist elucidate mechanisms underlying how completely different ailments impression sufferers with differing levels of severity. This has great implications for circumstances that impression individuals of African descent. In the end, our work utilizing samples from African populations, has the potential to considerably enhance well being outcomes in Africa. We’re thrilled to offer our purchasers with entry to this platform and consequently essential solutions to a few of their key analysis questions and hope to develop this service to the Olink® Discover platform sooner or later,” mentioned Dr Liam Bell, Supervisor of the D-CYPHR proteomic facility.
“Olink is immensely proud to see our expertise contributing to the excellent analysis efforts in South Africa. We all know that our expertise will additional stimulate the event of groundbreaking science, enhancing the well-being of individuals all over the world,” mentioned Jon Heimer, CEO of Olink. “That is an thrilling first step in what I’m assured shall be a fruitful and collaborative journey.”
Jan Medina, CFA
VP Investor Relations & Capital Markets
Cellular: +1 617 802 4157
Company Communications Supervisor
Cellular: +46 768 775 275
Olink Holding AB (Nasdaq: OLK) is an organization devoted to accelerating proteomics along with the scientific neighborhood, throughout a number of illness areas to allow new discoveries and enhance the lives of sufferers. Olink supplies a platform of services that are deployed throughout main pharmaceutical corporations and main scientific and educational establishments to deepen the understanding of real-time human biology and drive twenty first century healthcare via actionable and impactful science. The Firm was based in 2016 and is nicely established throughout Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.
DIPLOMICS (DIstributed PLatform in OMICS) is considered one of 13 Analysis Infrastructures established by the Division of Science and Innovation (DSI) via its South African Analysis Infrastructure Roadmap (SARIR).
This launch might comprise forward-looking statements inside the which means of relevant securities legal guidelines, together with the U.S. Personal Securities Litigation Reform Act of 1995, as amended, together with, with out limitation, statements relating to Olink’s technique, enterprise plans and focus. The phrases “might,” “will,” “may,” “would,” “ought to,” “count on,” “plan,” “anticipate,” “intend,” “imagine,” “estimate,” “predict,” “undertaking,” “potential,” “proceed,” “goal” and related expressions are meant to establish forward-looking statements, though not all forward-looking statements comprise these figuring out phrases. Any forward-looking statements on this press launch are based mostly on administration’s present expectations and beliefs as of the date hereof and are topic to plenty of dangers, uncertainties and essential components that will trigger precise occasions or outcomes to vary materially from these expressed or implied by any forward-looking statements contained on this press launch, together with, with out limitation, these associated to Olink’s enterprise, operations, provide chain, technique, objectives and anticipated timelines, together with for the supply of Olink Discover 3072 and the growth of the Discover platform, competitors, and different dangers recognized within the part entitled “Threat Components” in Olink’s Registration Assertion on Type F-1, as amended (File No. 333-253818) filed with the U.S. Securities and Alternate Fee (SEC) and within the different filings, reviews, and paperwork Olink information with the SEC sometimes. Olink expressly disclaims any obligation to replace any forward-looking statements on this launch to replicate any change in its expectations with regard thereto or any change in occasions, circumstances or circumstances on which any such assertion is predicated, except required by regulation or regulation.